Small molecule inhibition of Axl receptor tyrosine kinase potently suppresses multiple malignant properties of glioma cells

Oncotarget

Volumn 6, Issue 18, 2015, Pages 16183-16197

  Vouri, Mikaella ^a   An, Qian ^a   Birt, Matthew ^a   Pilkington, Geoffrey J ^a   Hafizi, Sassan ^a  

^a UNIVERSITY OF PORTSMOUTH   (United Kingdom)

Author keywords

Axl receptor tyrosine kinase; Glioma; Invasion; Small molecule inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; BGB 324; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH ARREST SPECIFIC PROTEIN 6; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE AXL; UNCLASSIFIED DRUG; AXL RECEPTOR TYROSINE KINASE; FUSED ALICYCLIC AROMATIC COMPOUND; GROWTH ARREST-SPECIFIC PROTEIN 6; MESSENGER RNA; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; R428 COMPOUND; SIGNAL PEPTIDE; TRIAZOLE DERIVATIVE;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOGENESIS; CELL DEATH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BRAIN NEOPLASMS; CELL CYCLE; CELL MOTION; DRUG EFFECTS; ENZYME IMMUNOASSAY; ENZYMOLOGY; GENETICS; GLIOMA; METABOLISM; PATHOLOGY; PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ADULT; APOPTOSIS; BENZOCYCLOHEPTENES; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL CYCLE; CELL MOVEMENT; CELL PROLIFERATION; GLIOMA; HUMANS; IMMUNOENZYME TECHNIQUES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR PROTEIN-TYROSINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRIAZOLES; TUMOR CELLS, CULTURED;

EID: 84937891847     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3952     Document Type: Article

References (36)

1. Lemke G. Biology of the TAM receptors. Cold Spring Harbor Perspectives in Biology. 2013; 5.
2. Verma A, Warner SL, Vankayalapati H, Bearss DJ and Sharma S. Targeting Axl and Mer kinases in cancer. Molecular Cancer Therapeutics. 2011; 10:1763-1773.
3. Hafizi S and Dahlbäck B. Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases. Cytokine & Growth Factor Reviews. 2006; 17:295-304.
4. Lew ED, Oh J, Burrola PG, Lax I, Zagórska A, Través PG, Schlessinger J and Lemke G. Differential TAM receptor- ligand-phospholipid interactions delimit differential TAM bioactivities. eLife. 2014; 3:e03385.
5. Studer RA, Opperdoes FR, Nicolaes GAF, Mulder AB and Mulder R. (2014). Understanding the functional difference between growth arrest-specific protein 6 and protein S: an evolutionary approach. Open Biology. 2014; 4:140121.
6. Pierce AM and Keating AK. TAM receptor tyrosine kinases: Expression, disease and oncogenesis in the central nervous system. Brain Research. 2014; 1542:206-220.
7. Seitz HM, Camenisch TD, Lemke G, Earp HS and Matsushima GK. Macrophages and dendritic cells use different Axl/Mertk/Tyro3 receptors in clearance of apoptotic cells. The Journal of Immunology. 2007; 178:5635-5642.
8. Lu Q and Lemke G. Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family. Science. 2001; 293:306-311.
9. Tsou W-I, Nguyen K-QN, Calarese DA, Garforth SJ, Antes AL, Smirnov SV, Almo SC, Birge RB and Kotenko SV. Receptor Tyrosine Kinases, TYRO3, AXL and MER, demonstrate distinct patterns and complex regulation of ligand-induced activation. Journal of Biological Chemistry. 2014; 289:25750-25763.
10. Schulz NT, Paulhiac CI, Lee L and Zhou R. Isolation and expression analysis of tyro3, a murine growth factor receptor tyrosine kinase preferentially expressed in adult brain. Molecular Brain Research. 1995; 28:273-280.
11. Zhong Z, Wang Y, Guo H, Sagare A, Fernández JA, Bell RD, Barrett TM, Griffin JH, Freeman RS and Zlokovic BV. Protein S protects neurons from excitotoxic injury by activating the TAM receptor Tyro3-phosphatidylinositol 3-kinase-Akt pathway through its sex hormone-binding globulin-like Rregion. The Journal of Neuroscience. 2010; 30:15521-15534.
12. Gely-Pernot A, Coronas V, Harnois T, Prestoz L, Mandairon N, Didier A, Berjeaud JM, Monvoisin A, Bourmeyster N, De Frutos PG, Philippe M and Benzakour O. An endogenous vitamin K-dependent mechanism regulates cell proliferation in the brain subventricular stem cell niche. Stem Cells. 2012; 30:719-731.
13. Ji R, Meng L, Jiang X, Cvm NK, Ding J, Li Q and Lu Q. TAM receptors support neural stem cell survival, proliferation and neuronal differentiation. PLoS ONE. 2014; 9:e115140.
14. Weinger J, Brosnan C, Loudig O, Goldberg M, Macian F, Arnett H, Prieto A, Tsiperson V and Shafit-Zagardo B. Loss of the receptor tyrosine kinase Axl leads to enhanced inflammation in the CNS and delayed removal of myelin debris during Experimental Autoimmune Encephalomyelitis. Journal of Neuroinflammation. 2011; 8:49.
15. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathologica. 2007; 114:97-109.
16. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine. 2005; 352:987-996.
17. Ohka F, Natsume A and Wakabayashi T. Current trends in targeted therapies for Glioblastoma Multiforme. Neurology Research International. 2012; 2012.
18. Dolecek TA, Propp JM, Stroup NE and Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro-Oncology. 2012; 14:v1-v49.
19. Keating AK, Kim GK, Jones AE, Donson AM, Ware K, Mulcahy JM, Salzberg DB, Foreman NK, Liang X, Thorburn A and Graham DK. Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity. Molecular Cancer Therapeutics. 2010; 9:1298-1307.
20. Hutterer M, Knyazev P, Abate A, Reschke M, Maier H, Stefanova N, Knyazeva T, Barbieri V, Reindl M, Muigg A, Kostron H, Stockhammer G and Ullrich A. Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with Glioblastoma Multiforme. Clinical Cancer Research. 2008; 14:130-138.
21. Vajkoczy P, Knyazev P, Kunkel A, Capelle H-H, Behrndt S, von Tengg-Kobligk H, Kiessling F, Eichelsbacher U, Essig M, Read T-A, Erber R and Ullrich A. Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival. Proceedings of the National Academy of Sciences. 2006; 103:5799-5804.
22. Ott M, Litzenburger UM, Sahm F, Rauschenbach KJ, Tudoran R, Hartmann C, Marquez VE, von Deimling A, Wick W and Platten M. Promotion of glioblastoma cell motility by Enhancer of Zeste Homolog 2 (EZH2) is mediated by AXL receptor kinase. Plos One. 2012; 7.
23. Wang Y, Moncayo G, Morin P, Jr., Xue G, Grzmil M, Lino MM, Clement-Schatlo V, Frank S, Merlo A and Hemmings BA. Mer receptor tyrosine kinase promotes invasion and survival in glioblastoma multiforme. Oncogene. 2013; 32:872-882.
24. Rogers AEJ, Le JP, Sather S, Pernu BM, Graham DK, Pierce AM and Keating AK. Mer receptor tyrosine kinase inhibition impedes glioblastoma multiforme migration and alters cellular morphology. Oncogene. 2012; 31:4171-4181.
25. Holland SJ, Pan A, Franci C, Hu Y, Chang B, Li W, Duan M, Torneros A, Yu J, Heckrodt TJ, Zhang J, Ding P, Apatira A, Chua J, Brandt R, Pine P, et al. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Research. 2010; 70:1544-1554.
26. Wilson C, Ye X, Pham TQ, Lin E, Chan SM, McNamara E, Neve RM, Belmont LD, Koeppen H, Yauch RL, Ashkenazi A and Settleman J. AXL inhibition sensitizes mesenchymal cancer cells to anti-mitotic drugs. Cancer Research. 2014; 74:5878-90.
27. Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH, Sherman PM, Holko M, Yefanov A, Lee H, Zhang N, Robertson CL, Serova N, Davis S, et al. NCBI GEO: archive for functional genomics data sets-update. Nucleic Acids Research. 2013; 41:D991-D995.
28. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine. 2005; 352:987-996.
29. Hafizi S and Dahlbäck B. Gas6 and protein S. FEBS Journal. 2006; 273:5231-5244.
30. Li Y, Jia L, Ren D, Liu C, Gong Y, Wang N, Zhang X and Zhao Y. Axl mediates tumor invasion and chemosensitivity through PI3K/Akt signaling pathway and is transcriptionally regulated by slug in breast carcinoma. IUBMB Life. 2014; 66:507-518.
31. Li Y, Jia L, Liu C, Gong Y, Ren D, Wang N, Zhang X and Zhao Y. Axl as a downstream effector of TGF-ß1 via PI3K/Akt-PAK1 signaling pathway promotes tumor invasion and chemoresistance in breast carcinoma. Tumor Biology. 2015; 36:1115-1127.
32. Rankin EB, Fuh KC, Taylor TE, Krieg AJ, Musser M, Yuan J, Wei K, Kuo CJ, Longacre TA and Giaccia AJ. AXL is an essential factor and therapeutic target for metastatic ovarian cancer. Cancer Research. 2010; 70:7570-7579.
33. Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, Choi YJ, Choi C-M, Kim S-W, Jang SJ, Park YS, Kim WS, et al. Activation of the AXL kinase causes resistance to EGFRtargeted therapy in lung cancer. Nature Genetics. 2012; 44:852-860.
34. Meyer AS, Miller MA, Gertler FB and Lauffenburger DA. (2013). The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triplenegative breast cancer cells. Science Signaling. 2013; 6:ra66.
35. An Q, Fillmore HL, Vouri M and Pilkington GJ. Brain tumor cell line authentication, an efficient alternative to capillary electrophoresis by using a microfluidics-based system. Neuro-Oncology. 2014; 16:265-273.
36. Schneider CA, Rasband WS and Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nature Methods. 2012; 9:671-675.